Connecting Life Sciences
VIENNA Highlights
Life Science City Vienna: 30 SMEs you must know page 6-7
i
Innovation made in Vienna: Hookipa Biotech is supercharging immunotherapies with $60 million
Spring & Summer 2018
page 8
Celebrating Innovation in Biotech & Medtech
bestofbiotech.at
© aws/vogus
aws BOB - Best of Biotech is an international two-stage life science business plan competition organized by the Austria Wirtschaftsservice on behalf of the Austrian Federal Ministry for Digital and Economic Affairs. Three out of four winners chose Vienna as the city in which to set up their life sciences business. Congratulations to all the outstanding awardees!
Macro Array Diagnostics (Vienna), 2nd prize sponsored by Roche Diagnostics and Roche Austria Macro Array Diagnostics is creating the first allergy test allowing a simultaneous measurement of total IgE and specific IgE covering close to 100% of globally relevant allergens. | macroarraydx.com
ImageBiopsy Lab (Vienna), 3rd prize sponsored by Boehringer Ingelheim IB Lab uses state-of-theart computer-vision and artificial intelligence technology to change the way in which bone diseases are being assessed and diagnosed, including knee osteoarthritis. | imagebiopsylab.com
MorphoMed (Vienna), LISAvienna Medtech Award MorphoMed focuses on tissue engineering based on its proprietary medical-silk technology. The lead product is a regenerative anterior cruciate ligament, which will fully restore the endogenous ligament. | morphomed.at
Why Vienna? © aws / Heribert Corn
BHS Technologies (Völs), 1st prize sponsored by Shire BHS is developing a disruptive medical device that will enhance the performance of microsurgical procedures for all participants - patient, surgeon and hospital. | bhs-technologies.com
Marlis Baurecht, Business area Entrepreneurship, Property Rights, Seedfinancing, aws aws.at
“
As a clear result of Austria’s current movement to promote innovation and growth, I am delighted to see a steady stream of innovative biotech and medical device start-ups opening up their doors here. Most of them have chosen Vienna as their home base.”
Dear readers! Starting a biotech or medical device company in Vienna means benefiting from a 360° support landscape nurturing a unique life sciences ecosystem. Various grants, loans and guarantees as well as free consulting services and flexible start-up offices are available in Vienna. The increased research premium of 14% makes Austria even more attractive. We strongly recommend that you consider Vienna when planning to start up or grow your company at the heart of Europe! Our technology experts are available to talk about all the support that is available here for developing tomorrow’s products, processes and services. Please contact us to help you find suitable lab space including the most modern start-up labs.
LISAvienna – Connecting Life Sciences
We offer core services at no charge Joint life science platform for the advancement of life sciences in Vienna Federal Ministry for Digital and Economic Affairs
Personalized support for innovative biotech, pharmaceutical and medical device companies - in Vienna, - that develop and market - new products, services and processes Connecting companies with development partners and key customers.
Did you know that all major biopharmaceutical companies ranked by sales run strategic offices in Vienna? Some even coordinate clinical trials on game-changing drugs at their premises in Austria. Other big players such as Boehringer Ingelheim, Octapharma and Ottobock make major investment decisions at their Vienna site that result in their increasing R&D and manufacturing facilities.
We hope you enjoy reading this edition of our biannual Highlights folder. Should you wish to provide us with feedback, please contact the LISAvienna team. More up-to-date information on the life sciences sector in Austria and Vienna including new statistics and an updated directory, will be available in November. Have a fruitful trade fair, partnering and conference season! Peter Halwachs and Johannes Sarx LISAvienna Executive Board
Meet us at trade shows & exhibitions BIO-Europe Spring 2018 Amsterdam, March 12-14, 2018
BIO International Convention Boston, June 4-7, 2018
MT-Connect and MedTech Summit Nuremberg, April 11-12, 2018
ACC Annual Scientific Meeting & Clinical Lab Expo Chicago, July 29 - August 2, 2018
BioTrinity 2018 London, April 23-25, 2018 conhIT 2018 Berlin, April 25-27 Bio€quity Europe 2018 Ghent, May 14-16, 2018 HIMSS Europe 2018 Sitges, Barcelona, May 27-29, 2018
BIO Latin America Sao Paulo, September 4-5, 2018
Your partners at LISAvienna (ltr): Andrea Jan Coleselli (Administration, Controlling and Events), Johannes Sarx (Managing Director), Brigitte Tempelmaier (Project Manager Marketing & PR), Peter Halwachs (Managing Director), Martin Mayer (Technology Expert Medtech), Jürgen Fuchs (Technology Expert Biotech & Pharma)
Contact us and benefit from our services
Information & Consulting:
Networking & Matching:
Expertise:
Marketing:
Tips and contacts relating to sponsorship, private financing options, lab space in Vienna, development partners, leading customers and internationalization
BIO-Europe 2018 Copenhagen, November 5-7, 2018 MEDICA & COMPAMED November 12-15, 2018 We reserve the right to make changes.
in cooperation with:
Need a lab for your start-up in Vienna? LISAvienna has compiled a factsheet on suitable lab space. If you would like to explore options in Vienna, please contact the LISAvienna team.
2
© LISAvienna / Beranek
Vienna is highly attractive for talent and educates the largest number of students in the German-speaking region. We are proud of hosting a vibrant international research community and a growing number of start-ups in Vienna. On our cover, we already introduced you to some of the most promising newcomers in the city. Please see page 3 for additional start-ups and page 6-7 for more advanced companies. In addition, do not miss the opportunity to learn more about Hookipa Biotech’s recent investment deal on page 8.
Analyses, background information, reports and studies relating to life sciences in Vienna
Newsletter & Tweets
Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading customers and investors worldwide
Electronic and printed news items from the field of life sciences in Vienna
Stay updated on the hottest news from the life science city Vienna! Subscribe to our newsletter at LISAvienna.at Follow us on Twitter @lifesciencevie
STARTING UP IN VIENNA 360° Support for the Life Sciences
Vienna: · Highest quality of life worldwide
· Largest talent pool in the German speaking region · Outstanding basic and clinical research · Prime conference destination
Austria:
Located at the heart of Europe
· Stable political and economic framework · 14% research tax credit
Flexible start-up labs
€ 800,000 Seedfinancing
· Maximum corporate tax rate: 25% · Tailor-made funding opportunities
Get in touch!
LISAvienna.at
aws.at
FWF.ac.at
INiTS.at
Experienced support agencies
Shared research infrastructure
FFG.at
lifescienceaustria.at
viennabusinessagency.at
Newcomers Name Allcyte GmbH allcyte.com Ares Genetics GmbH ares-genetics.com CCORE Technology GmbH criticalcoretechnology.com Contextflow GmbH contextflow.com Heartshield heartshield.net IB Lab GmbH imagebiopsylab.com MorphoMed GmbH morphomed.at MVT Biotechnology GmbH mvtbio.com MyeloPro Diagnostics and Research GmbH myelopro.com Nuvonis Technologies GmbH nuvonis.com OVARTEC GmbH PhagoMed Biopharma GmbH phagomed.com Ribbon Synthetic Biolabs ribbonbiolabs.com
www.wko.at/wien/aw
wwtf.ata
Why Vienna? Founded in 2017 2017 2017 2016 *) 2016 2017 2017 2015 2017 2017 2017 *)
“
Seedfinancing x
x x
x
The above list, which is not exhaustive, includes companies that opened their doors in Vienna recently as well as those that were newly added to the aws Seedfinancing portfolio in 2017. The symbol “*)” marks two start-up projects that have received significant funding via the Vienna Business Agency’s “Co-Create 2017” funding program.
VIENNA Highlights 01/2018
Access to private equity and licensing partners Growing life science network
Cost free coaching
International airport investinaustria.at
Ideas & Talent
Great business environment
© Christian Husar
We accompany you on your way to success. Enter the ecosystem now!
€ 500,000 for R&D projects
€ 200,000 for PreSeed
Eva Czernohorszky, Head of Technology Services, Vienna Business Agency viennabusinessagency.at
Vienna offers an extremely tight network of funding opportunities as well as everything else needed to start up life sciences companies and enable them to grow. Join our vibrant biotech and medical device community and become one of our skyrocketing success stories!”
Vienna has joined Start Alliance Helping ideas to spread faster startalliance.net
3
Bulletin
Board
ENGAGE WITH THE RIGHT PARTNE RS
AT EUROPEʼS LA RGEST SPRING TIME BIOTECH PART NERING EVEN T
SzeleSTIM to be grante d H2020 phase 1 SME support
© Wien Tourismus
/ Peter Rigaud
SzeleSTIM is focusing on we arable bio-electronic device s for Auricular Vagus Nerve Stim ulation, allowing minimally invasive and non-pharmacological pain therapy adapted to the ind ividual patient. szelestim.com
invest in Vienna to im e lh e g In r e g Boehrin er Mirau ger Ingelheim / Rain © Copyright Boehrin
V I E N N A , AU STRIA // MA RC H 2 5 – 27, 2 019
in Themis raises € 10 million series C financing
be used to advance The GHIF-led investment will ical vaccine development Themis’s clinical and pre-clin advanced vaccine st programs, including its mo which the company on s, viru a against chikunguny se 2 results. recently reported positive Pha
t chieve firs Evotec a d y n g a lo s o ic c Biolog uno-on APEIRON € 200 million imm in e n milesto d ith Sanofi le leads an alliance w all molecu m logy s o n c o n n -o o immuno llaborati o in c s ic ie g p te ra a n c, a d on the The str gics, Evote ew t-generati lo x e io n B r N fo O ts targe sed, n APEIR n undisclo in 2015 by a f p o u t t n e ent has e s s m wa l developm plit advance a e ic th lin , w -c o re be s Sanofi. N te-stage p million will cule into la t. The € 3 n e m y small mole a p . s e a mileston o biotech companie triggered e tw th n e e tw equally be m iologics.co apeiron-b
4
themisbio.com
Arsanis announces closing of Init ial Public Offering
Arsanis, Inc. (NASDAQ:ASNS) is a clinic al-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. The gross proceeds to Arsanis from the offering were $46.0 million, before deducting underwriting discount s and commissions and other offering expenses. arsanis.com
© Sempermed
Sempermed to intr od environmentally frie uce nd examination gloves ly
The nitrile examinatio n glove Sempercare® Green is not only gre en in color, this latexfree glove is produce d without any rubber accelerators or chlor ine and saves on gas, electricity and CO em issions during the 2 production process . reglove-yourself.com
Lab to digitalize Siemens to open Living bioprocesses in Vienna cesses.
biopro , simulating and optimizing The lab focuses on modeling small batches. in gs tion of personalized dru One use case is the produc more flexible ch mu e om g processes to bec This requires manufacturin cess. automation are keys to suc than today – digitalization and siemens.com/at/de
FDA grants O rp Zytoprotec’s han Drug Designation to unique dialys is treatment of patients with fluid for the end-stage re disease nal
Zytoprotec is cu rrently preparin g a pivotal Phas protec® in 300 e III clinical trial patients in Euro with PDpe and the Uni designation will ted States. The provide Zytopr orphan otec with seve including marke ral developmen t exclusivity for t incentives up to seven ye ars upon FDA zytoprotec.com approval.
A: and IMB m Vienna n e g o x e L fro quencing ss story eration se uct e n c e g c tu x s e A nd n prod ptomics a LAMseq
ri S ched the the transc RNA. Kits Lexogen, m Vienna, has laun encing of u q e s lic o o fr b meta e Austrian company roughput loped at th chnology th e v h e ig d h y r g iote family fo technolo olecular B eing marketed on a new titute of M s yb In d ’ are based a s e e lr c d are a of Scien Center an io Academy B a n n the Vie (IMBA) at e world. around th d e and us om lexogen.c
ging BioIma n a i r t s B) ff: Au Kick-o ry Board (ABI ltimodal Imagu elated M ustry Board to Indust MI (Corr d
an In tria/C nd blished ing Aus aging a BioImag ustria) has esta rested in bioim d n te rts a eA olders in rted effo ing Nod ll stakeh Austria. Conce g scientists, a t c e n con agin g in al rocessin ntists, im ster multimod fo image p etween life scie l il w dustry sb activitie experts, and in r tion. te a u v p com e inno v ri d d n a imaging tria.at ing-aus bioimag
Ottobock to celebrate twen ty years of C-Leg
Manufactured in Vienna only, C-Leg is the most popular computerized aboveknee prosthetic leg in the world. Back in 1999, Ottoboc k received the Austrian Innovation Award for develop ing the revolutionary C-Leg. ottobock.at
Interested in bioeconomy & biopharma?
Check out technologies and ideas for joint projects available at the Austrian Centre of Industrial Biotechnology! www.acib.at/industry
I
Coming so on The Vienn a Business Agency’s Vienna Bio Center Start-up L abs viennabusin essagency. at
Get connected @
VIENNA Highlights 01/2018
Vienna
(@lifesciencevie)
5
Life Sciences City Vienna: 17 companies with clinical stage pipelines Vienna’s red biotech community is particularly rich in platform technologies that are leading to promising new drug candidates and medical devices. Our unique start-up ecosystem, together with experienced entrepreneur networks and negotiation skills, have yielded spectacular equity investments and licensing deals. These are enabling product candidates to progress into clinical development stages.
Below is a list of Vienna-based companies that have succeeded in starting clinical studies. Together, these account for:
Name
Phase I
AOP Orphan Pharmaceuticals AG aoporphan.com Innovative solutions for rare diseases
16 product candidates with ongoing phase II trials or ready for phase II
APEIRON Biologics AG apeiron-biologics.com Immunological approaches to treat cancer
13 product candidates with ongoing phase III trials or ready for phase III
APEPTICO Forschung und Entwicklung GmbH apeptico.com Peptide-based drugs targeting life-threatening diseases
In 2017, Vienna even witnessed the European Commission’s marketing authorization for APEIRON Biologics’ promising new antibody-based immunotherapy for a rare pediatric cancer, neuroblastoma.
Arsanis Biosciences GmbH arsanis.com Targeted monoclonal antibodies to address infectious diseases
Truly overwhelming!
Hookipa Biotech AG hookipabiotech.com Active immunization therapies for infectious diseases and cancer
© Apeiron Biologics
“
Hans Loibner, CEO, APEIRON Biologics AG
I have been living in Vienna for over 70 years, and it’s a great place. I’ve been the CEO of biotech companies in Vienna for almost 20 years, and it’s a great location for these too. We have valuable support and a positive climate (and I’m not referring to our December weather…).”
Phase III
AFFiRiS AG affiris.com Active immunization to treat or prevent chronic diseases
10 product candidates with ongoing phase I trials or ready for phase I
Why Vienna?
Phase II
Biomay AG biomay.com Innovative allergy therapeutics F4 Pharma Ges.m.b.H. i.G. f4-pharma.com Drugs targeting vascular leak syndrome and inflammation
Marinomed Biotech AG marinomed.com Innovative immunological and antiviral treatments Nabriva Therapeutics AG nabriva.com Novel antibiotics to treat infectious diseases Panoptes Pharma GmbH panoptes-pharma.com Innovative small molecule drugs to treat eye diseases ProFem GmbH profem.at Innovative drugs for the treatment of gynecological diseases Sanochemia Pharmazeutika AG sanochemia.at Diagnostics and drugs targeting neurology and oncology Themis Bioscience GmbH themisbio.com Vaccines against emerging and specialist indications
Are you interested in learning more about clinical stage development projects in Vienna? LISAvienna has compiled a factsheet on 39 product candidates. Several of them are available for partnering. Please contact the LISAvienna team for further details.
Valneva SE valneva.com Innovative life-saving vaccines against infectious diseases Vivaldi Biosciences AG vivaldibiosciences.com Developing more effective flu vaccines Zytoprotec GmbH zytoprotec.com Cytoprotective therapeutics for renal replacement therapy
The above list is not exhaustive.
Biologics
Small Molecules
Vienna is proud to host award-winning enterprises! Acticell: Gewinn Award 2017
DirectSens: WKW Mercur Award 2017
Acticell develops and sells safe and environmentally friendly solutions for emerging technologies in the textile industry including unusual dyeing effects or localized bleaching.
DirectSens develops 3rd generation biosensors, especially for carbohydrates such as lactose or glucose, that meet the needs of continuous measurements.
acticell.at
directsens.com
Evologic Technologies: WKW Mercur Award 2017 Evologic applies advanced technologies from red biotech to develop bioprocesses for white biotech products including mycorrhizal fungi as fertilizers for agriculture. evologic-technologies.com
30 SMEs you should know 13 companies with unique eHealth expertise IT has revolutionized health care in recent years and there is no end in sight for this major transformation process. In actual fact, it would seem we have only just begun to understand where big data, network analysis and artificial intelligence might take us in the future. Evidently, there are many market niches for highly skilled and creative entrepreneurs.
© Tiani Spirit
Vienna is proud to be called home for a growing number of innovative eHealth companies that are successfully addressing such market niches. We have selected 13 companies that cover a plethora of topics for our brief introduction below. You are warmly invited to connect to these hot spots of eHealth expertise!
“ Martin Tiani, CEO, Tiani Spirit GmbH
Austria’s healthcare and life science industry is very well known by experts all over the world. We are proud to have our headquarters in Vienna and to be part of this vibrant atmosphere regarding technology, innovations and digitalization.”
Name
Main product or service
AHIT Animal-Health-IT GmbH ahit.at Innovative applications and IT-services for agriculture, including vets and livestock owners
Animal Health Record: integrative electronic health record system for all stakeholders in animal husbandry
CogVis Software und Consulting GmbH cogvis.at Smart home products for active and assisted living
fearless life comfort system: automatic fall detection, no device needs to be worn, no camera
contextflow GmbH contextflow.com Image-based deep learning tools to improve medical decision making
contextflow search engine: a tool for radiologists to find similar reference cases and diagnoses quickly
Diagnosia Internetservices GmbH diagnosia.com Tools for making evidence-based medicine simple
Diagnosia app: rapid access to information on drugs and their interplay, for medical professionals only
dwh GmbH dwh.at System analysis, modeling and simulation for informed decision-making
Decision support: tailor-made services for policy making, the pharmaceutical industry or health-technology assessment
ImageBiopsy Lab www.imagebiopsylab.com Tools for radiologists/orthopedics to improve standardized assessment of bone diseases
Knee check-up package: a positioning device and software for tracking osteoarthritis, rheumatoid arthritis, and osteoporosis
Medexter Healthcare GmbH medexter.com Improving quality and safety in patient care by integrating intelligent clinical decision support
ArdenSuite: flexible CDS technology platform for hospitals - both patient and population specific
mySugr GmbH mysugr.com Market leader in digital diabetes management, part of the Roche family
mySugr Bundle: unlimited test strips, an Accu-Chek® Guide meter, the mySugr app and diabetes advice wherever and whenever you want
piur imaging GmbH piurimaging.com Tomographic ultrasound allowing for safe and cost-effective 3D vascular diagnostics
PIUR tUS: a tomographic function for regular ultrasound devices with a digital video output - no x-rays or contrast agent required
Platomics GmbH platomics.com Digital infrastructure for personalized medicine to support medical doctors, hospitals, labs and test kit providers
PlatoX™: user-friendly digitalization of workflows to analyze genes and genomes - meets data security requirements
Recognosco GmbH recognosco.net Professional speech recognition platform for efficient, high quality document creation
RSDK: Software Development Kit (SDK) to speech-enable dictation and document management solutions
Scarletred Holding GmbH scarletredvision.com Tools for standardized, digital skin assessment
SCARLETRED®Vision: app, patch and QR system for digital dermatology, uncoupling medical from personal data
Tiani Spirit GmbH tiani-spirit.com Standards-based interoperability in healthcare IT
Spirit Electronic Health Record: Software to standardize, connect and exchange information between healthcare systems
The above list is not exhaustive.
LISAvienna Partnering SCARLETRED: WSA Young Innovators 2017 SCARLETRED®Vision revolutionizes dermatology through standardized digital documentation and objective digital assessment of visual skin changes. scarletredvision.com
Healthcare by Big Data At the Complexity Science Hub Vienna, the world’s first nationwide healthcare system simulator is being developed. csh.ac.at
Tailor-made schedule to meet all the Vienna based biotech and medical device start-ups you are interested in One day in Vienna, for global players and investors only
7
Innovation made in Vienna: Hookipa Biotech is supercharging immunotherapies with $60 million Hookipa Biotech AG, a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases in Vienna, recently announced that it has raised $59.6 million (€50.0 million) in an oversubscribed Series C financing. The proceeds of the fundraising will primarily be used to advance two proof-of-concept clinical trials of Hookipa’s lead development programs: a phase 2 study of the company’s prophylactic Cytomegalovirus (“CMV”) vaccine in solid organ transplant patients, and a phase 1 study of its TheraT®-based active immunization therapy in patients with head & neck squamous cell carcinoma. In addition, Hookipa plans to expand its technology platform into other areas of disease, such as prostate cancer.
Investors trust in Hookipa
Smart facilities in smart cities Founded in Vienna back in 2011, Hookipa today operates facilities at the Vienna BioCenter, which is one of Austria’s most well-known biotech hot spots, In 2017 Hookipa decided to open a US site at the Alexandria Bio Incubator in New York where Chief Medical Officer Igor Matushansky and Head of Clinical Programs Andy Hwang are based.
Hookipa Biotech at a glance
The financing round was led by an undisclosed blue chip U.S. public investment fund specializing in life sciences, along with other new investors: HBM Partners, Hillhouse Capital, Sirona Capital and strategic investor Gilead. All current Hookipa investors - Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners - participated in the round.
• Founded in 2011 • 51 employees • Arenavirus-based vector technologies TheraT® and Vaxwave® available for strategic partnerships to develop next generation immunotherapies
Experienced team promoting a great pipeline Hookipa Biotech stands out from the European biotech community thanks to its highly innovative platform technologies and its ability to raise significant amounts of capital to move its promising clinical-stage drug candidates forward. Hookipa’s team, which represents a melting pot of expertise and heterogeneous networks, is the secret of its success: The company benefits from many years of experience in collaborating with the private equity sector, from partnering with research communities worldwide and from gaining essential industry know-how from distinguished players such as Bayer, Baxter, Evotec, Daiichi Sankyo, GlaxoSmithKline, MorphoSys, Novartis, uniQure and Valneva.
• Headquarters located at the Vienna BioCenter
hookipabiotech.com
© Hookipa Biotech
Why Vienna?
© Hookipa Biotech
LISAvienna Life Science Austria Vienna Walcherstrasse 11A 1020 Vienna, Austria
PHONE FAX E-MAIL WEB
+ 43 (0) 1 50175 358 + 43 (0) 1 50175 900 office@LISAvienna.at www.LISAvienna.at
JAldag@hookipabiotech.com
The Austrian capital is an important and competitive hub at the center of Europe’s biotech and life sciences sector. It provides an environment that is forward-looking, dynamic, and challenging, which in turn increases the industry´s capacity to innovate.”
© Hookipa Biotech
LISAvienna is a joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.
Layout: Eva Aichinger
“
Joern Aldag CEO Hookipa Biotech AG